![alzheimer](https://igcpharma.com/wp-content/uploads/2024/04/Positive-Results-IGC-AD1.jpg)
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.